EUCTR2013-003558-26-GB进行中（未招募）1 期
A Prospective, Randomized, Controlled, Study Evaluating the Safety and Efficacy of EVICEL® used for Suture-line sealing in Dura-Mater Closure during Paediatric Neurosurgical Cranial Procedures - The Paediatric EVICEL® Neuro Study
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Ethicon Inc
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Preoperative
- •1. Patient undergoing elective or urgent craniotomy/craniectomy for pathological processes in the posterior fossa (such as benign or malignant tumors, vascular malformation, and Chiari 1 malformations) or in the supratentorial region and who are demonstrated to have persistent CSF leakage following primary attempt at suture closure of the dural incision;
- •2. Administration of perioperative antibiotic prophylaxis;
- •3. Patients who are less than 18 years of age;
- •4. Patients who are able and willing to comply with the procedures required by the protocol;
- •5. The subject’s parent/legal guardian must be willing to give permission for the subject to participate in the trial, and provide written informed consent for the subject. In addition, assent must be obtained from paediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the trial.
- •Intraoperative
- •1. Surgical wound classification Class I. Penetration of mastoid air cells during partial mastoidectomy is permitted;
- •2. The cuff of native dura along the craniotomy edge on each side is wide enough based on surgeon’s judgment to facilitate suturing and to allow for sufficient surface area for adherence of the investigational product.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 42
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Preoperative:
- •1. Subjects with a dura lesion from a recent surgery that still has the potential for CSF leakage.
- •2. Conditions or treatments significantly compromising the immune system (such as AIDS);
- •3. Known hypersensitivity to the components (human fibrinogen, arginine hydrochloride, glycine, sodium chloride, sodium citrate, calcium chloride, human thrombin, human albumin, mannitol and sodium acetate) of the investigational product;
- •4. Hydrocephalus (Occlusive Hydrocephalus is permitted when caused by posterior fossa pathology to be treated, i.e. hydrocephalus is due to a blockage caused by a tumor to be removed);
- •5. Existing CSF (ventricular, etc.) drains, Shunts, Cushing/Dandy cannulation or Burr holes which damage the dura.
- •6. Female subjects of childbearing potential with a positive urine or serum pregnancy test within 24 hours prior to surgery;
- •7. Female subjects who are breastfeeding, pregnant, or intend to become pregnant during the clinical study period;
- •8. Participation in another clinical trial with exposure to another investigational drug or device within 30 days prior to enrollment or expected during the study period;
- •9. Scheduled or foreseeable surgery within the follow-up period.
- •Intraoperative:
- •1. Dura injury during craniotomy/craniectomy that cannot be eliminated by widening the craniotomy/craniectomy to recreate the native dura cuff;
- •2. Use of implants made of synthetic materials coming into direct contact with dura (e.g., PTFE patches, shunts, ventricular and subdural drains);
- •3. Planned use of dural patches after primary suture closure of the dura;
- •4. Placement of Gliadel Wafers;
- •5. Persistent signs of increased brain turgor;
- •6. Patient has a gap between durotomy edges of greater than 2mm after primary dural closure.
- •7. Intersecting durotomy scars in the surgical path from a previous operation that cannot be completely removed by the planned dura resection;
- •8. Two or more separate dura defects, including defects from ventricular cannulation and ventricular-peritoneal shunting;;
- •9. Major intraoperative complications that require resuscitation or deviation from the planned surgical procedure
研究者
相似试验
进行中（未招募）
1 期
A study of the safety and effectiveness of EVICEL® as a treatment in addition to standard techniques of stopping bleeding during abdominal surgery in childreAbdominal, Retroperitoneal, Pelvic or Thoracic (Non-Cardiac) SurgeryEUCTR2013-003401-26-BEEthicon Inc.40
进行中（未招募）
1 期
A study of the safety and effectiveness of EVICEL® as a treatment in addition to standard techniques of stopping bleeding during abdominal surgery in childreAbdominal, Retroperitoneal, Pelvic or Thoracic (Non-Cardiac) SurgeryEUCTR2013-003401-26-GBEthicon Inc.40
进行中（未招募）
1 期
A study evaluating the effect of EVARREST® Fibrin Sealant Patch as as an adjunct to haemostasis in controlling mild to moderate bleeding during open surgery in paediatric patientsEUCTR2013-003557-24-GBEthicon Inc40
进行中（未招募）
1 期
A study evaluating the effect of EVARREST® Fibrin Sealant Patch as as an adjunct to haemostasis in controlling mild to moderate bleeding during open surgery in paediatric patientsMild or moderate hepatic parenchyma or soft tissue bleeding duringopen, abdominal, retroperitoneal, pelvic and thoracic (non-cardiac) surgeryEUCTR2013-003557-24-BEEthicon Inc40
已完成
不适用
A Clinical study to evaluate the glycemic index of 11 rice samples in healthy volunteersCTRI/2011/10/002035Marico Ltd30